Drug intelligence / Profile preview

AXA1957

Development stage: Unknown
Lead developer: Axcella
Modality: Small Molecules
Administration: Oral

Overview

AXA1957 is a novel, orally administered endogenous metabolic modulator (EMM) composition specifically designed to simultaneously support metabolic, inflammatory, and fibrotic pathways associated with liver health. It was developed as a potential therapeutic for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Clinical studies showed it could reduce markers of metabolism (MRI-PDFF), inflammation (ALT, CK-18, cT1), and fibrogenesis (proC3).

Beyond the preview

Go deeper on AXA1957.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXA1957.

Explore the full profile